ShareThis Page
MRI advance may detect more cancer |

MRI advance may detect more cancer

| Thursday, June 19, 2003 12:00 a.m

BOSTON — An enhanced type of MRI can detect much smaller tumors than ever before — some tinier than a pea — in an advance that could open a new age in diagnosing cancer without surgery, researchers say.

The experimental technique examines the lymph nodes for signs of spreading cancer.

Doctors already routinely use MRIs to check the lymph nodes to see whether cancer that originated somewhere else in the body — say, in the breast or the prostate gland — is spreading. But the enhanced technique proved superior to conventional MRIs when tested with cancer that had spread from the prostate.

And the leader of the research, Dr. Mukesh Harisinghani, said his team also has had preliminary success using the approach to detect the spread of breast, testicular, bladder and kidney cancer.

In the prostate study, the technique found 63 cancerous lymph nodes in 33 patients. Conventional magnetic resonance imaging, or MRI, would have missed 71 percent of the nodes, and the spreading cancer would have gone undetected in nine patients.

“Even if it only works this well for prostate cancer, it’s a significant advance,” said Dr. Jeffrey Brown, a radiologist at Washington University in St. Louis.

Earlier detection of spreading prostate cancer would allow more aggressive treatment sooner, help doctors track the response, and spare some patients unnecessary removal of the prostate gland or lymph nodes. About 200,000 prostate cancer cases are diagnosed each year, and 32,000 people die from it.

The Food and Drug Administration is considering whether to approve the new technique. It is unclear when the FDA might decide.

Dr. Samuel Wickline, who studies imaging at Washington University, said this method and others like it will eventually “allow us to diagnose things that you can’t even see with any imaging” now in use.

The study, funded partly by the National Cancer Institute, was carried out by Massachusetts General Hospital in Boston and University Medical Center in Nijmegen, the Netherlands. The findings appear in today’s New England Journal of Medicine.

The method relies on minuscule magnetic particles, known as nanoparticles, to enhance an MRI. Acting like a television’s contrast dial, the injected particles collect in the immune system’s lymph nodes and create a clearer separation between dark and light areas in the image.

Imaging systems have never reliably shown tumors this small before anywhere in the body. Up to now, the smallest tumors detectable by MRI have been about four-tenths of an inch — the size of a fingernail.

Conventional MRI uses a magnetic field, which allows doctors to see enough only to gauge the size of lymph nodes. Nodes bigger than four-tenths of an inch are generally considered cancerous; however, they are not always cancerous, while some smaller nodes are. The new technique shows detail within the nodes that reveals cancer’s presence.

The researchers gave patients an imaging agent known as lymphotropic superparamagnetic nanoparticles, which are specks of iron oxide less than a billionth of an inch across. Normally, the liver sucks up imaging agents before they reach the lymph nodes, but these particles are so small, they seep into the lymph system.

The technique appeared to work in cancerous lymph nodes from two-tenths to four-tenths of an inch, which would normally go unnoticed with regular MRI. It detected 96 percent of cancerous nodes that size, compared with a detection rate of 29 percent for regular MRI, and it found 41 percent of cancerous nodes smaller than two-tenths of an inch, which are invisible to conventional MRI.

When spreading cancer has already reached the lymph nodes, doctors typically order radiation or hormonal treatments.

The researchers did not report any major side effects from the imaging agent.

“I would anticipate that it’s going to get approved, and I would anticipate that it’s going to be a big seller,” said Dr. Otis Brawley, a cancer specialist at Emory University in Atlanta.

Categories: News
TribLIVE commenting policy

You are solely responsible for your comments and by using you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.